NRAS Wildtype

CI-VAR-00004734Explore in graph →CIViC 4465

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
NRAS Wildtype	Cetuximab	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11660 In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC) PMID 33090333 · Fisher et al., 2020 · Open in CIViC	civic
Malignant Breast Neoplasm1
NRAS Wildtype	Cetuximab	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11656 In a clinical study of 49 patients, 10 patients with Breast Cancer (BC) and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. PFS of 6.7 weeks (95% CI… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Colorectal Neoplasm1
NRAS Wildtype	Chemotherapy + PanitumumabCombination	Predictive	A	Supports Sensitivity Response	4	submitted	EID11270 In this phase III, randomized, open-label trial, 377 patients with wild-type KRAS exon two were randomized 1:1 to receive panitumumab 6 mg/kg IV on day 1 of each 14-day cycle plus BSC or BSC alone. Th… (full text at CIViC) PMID 27736842 · Kim et al., 2016 · Open in CIViC	civic

Malignant Ovarian Neoplasm1
NRAS Wildtype	Cetuximab	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11662 In a clinical study of 49 patients, 29 patients with Ovarian Cancer and wild-type NRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of 8 weeks (95% CI, 6.… (full text at CIViC) PMID 33090333 · Fisher et al., 2020 · Open in CIViC	civic